Cargando…
Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine
Cysteamine is currently the only therapy for nephropathic cystinosis. It significantly improves life expectancy and delays progression to end-stage kidney disease; however, it cannot prevent it. Unfortunately, compliance to therapy is often weak, particularly during adolescence. Therefore, finding b...
Autores principales: | De Leo, Ester, Taranta, Anna, Raso, Roberto, Polishchuk, Elena, D’Oria, Valentina, Pezzullo, Marco, Goffredo, Bianca Maria, Cairoli, Sara, Bellomo, Francesco, Battafarano, Giulia, Camassei, Francesca Diomedi, Del Fattore, Andrea, Polishchuk, Roman, Emma, Francesco, Rega, Laura Rita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026248/ https://www.ncbi.nlm.nih.gov/pubmed/36300303 http://dx.doi.org/10.1093/hmg/ddac266 |
Ejemplares similares
-
Mitochondrial Dynamics of Proximal Tubular Epithelial Cells in Nephropathic Cystinosis
por: De Rasmo, Domenico, et al.
Publicado: (2019) -
Benefits and Toxicity of Disulfiram in Preclinical Models of Nephropathic Cystinosis
por: Taranta, Anna, et al.
Publicado: (2021) -
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011) -
Analysis of CTNS gene transcripts in nephropathic cystinosis
por: Taranta, Anna, et al.
Publicado: (2010) -
Multisystem involvement, defective lysosomes and impaired autophagy in a novel rat model of nephropathic cystinosis
por: Krohn, Patrick, et al.
Publicado: (2022)